ArticleEye (London, England)2023
Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy.
Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Subthreshold Micropulse Laser Versus Oral Spironolactone in Chronic Central Serous Chorioretinopathy: A Quasi-Randomized Controlled Trial.Translational vision science & technology · 2024Trial
- Towards an objective classification of pachychoroid disease and its risk of progression.Eye (London, England) · 2026Article
- Evaluation of choriocapillaris perfusion changes in chronic central serous chorioretinopathy following Half-Dose photodynamic therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration.Ophthalmology and therapy · 2026Article
- Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.Ophthalmology and therapy · 2026Article
- Distinct Pathogenic Mechanisms of Neurodegeneration in Pachychoroid Pigment Epitheliopathy Versus Intermediate Age-Related Macular Degeneration.Ophthalmology and therapy · 2025Article
- Ellipsoid zone reflectivity changes after idiopathic epiretinal membrane peeling: a pilot study.International ophthalmology · 2025Article
- Choroidal Remodeling After Subthreshold Micropulse Laser in Chronic Central Serous Chorioretinopathy: Short-Term Outcomes.Journal of clinical medicine · 2025Article
- Choroidal and Choriocapillaris OCT-A Analysis in Patients Affected by Active Central Serous Chorioretinopathy.Translational vision science & technology · 2024Article
- OCT analysis and MPOD assessment in patients affected by retinitis pigmentosa.Scientific reports · 2024Observational
- Characterization of Vortex Vein Drainage System in Healthy Individuals Imaged by Ultra-Widefield Optical Coherence Tomography Angiography.Translational vision science & technology · 2024Article
- Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy.Journal of ophthalmology · 2024Article
- Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye.Ophthalmology and therapy · 2023Article
- Choroidal and Retinal Imaging Biomarkers in Different Types of Macular Neovascularization.Journal of clinical medicine · 2023Article
- Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Factors related to changes in visual symptoms after successful photodynamic therapy in central serous chorioretinopathy.PloS one · 2023Article
- En Face Choroidal Vascularity in Both Eyes of Patients with Unilateral Central Serous Chorioretinopathy.Journal of clinical medicine · 2022Article
- Long-Term Eplerenone Treatment in Peripapillary Pachychoroid Syndrome: A Case Series.Case reports in ophthalmologyArticle
- Effect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate choroidal vascularity index (CVI) changes after oral eplerenone treatment in chronic central serous chorioretinopathy (cCSC) using the Spectral-domain (SD)-Optical Coherence Tomography (OCT) with enhanced depth imaging (EDI) mode.
methodsThirty-six eyes of 18 patients suffering from cCSC with monolateral foveal subretinal fluid (FSRF) successfully treated with oral eplerenone treatment and 18 age-matched healthy subjects were enroled in this retrospective study. EDI-OCT images obtained using Heidelberg Spectralis OCT device in patients with cCSC and FSRF (group 1); fellow eye (group 2) or healthy patients (healthy) were exported and then imported into image analysis ImageJ software for subsequent quantitative analysis. The main outcome measures were luminal area (LA) and CVI.
resultsA higher value of CVI was detected in group 1 compared to healthy eyes (p = 0.006). LA and CVI significantly reduced during follow up in group 1 and group 2. LA at 120 days was significantly lower compared to all previous time points both in group 1 and group 2 (p < 0.001). Median and [1st -3rd quartile] CVI values were 0.8 [0.7; 1.1] at baseline, 0.8 [0.7; 0.9] at 30 days; 0.7 [0.6; 0.9] at 60 and 90 days and 0.6 [0.5; 0.8] at 120 days in group 1 (p = 0.007) and 0.7 [0.6; 0.9] at baseline, 0.7 [0.7; 0.8] at 30 days; 0.7 [0.6; 0.7] at 60 and 90 days and 0.6 [0.6; 0.7] at 120 days in group 2 (p = 0.018).
conclusionsChoroidal vascularity index reduced in cCSC patients after oral eplerenone treatment during follow up both in eyes with SRF and fellow eyes thus demonstrating the effectiveness of mineral corticoid receptor antagonists in recovering choroidal morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.